Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Junqueira, Caroline ^a,b   Guerrero, Ana Tereza ^a   Galvão Filho, Bruno ^a,b   Andrade, Warrison A ^a,b,c   Salgado, Ana Paula C ^a   Cunha, Thiago M ^d   Ropert, Catherine ^a   Campos, Marco Antônio ^a   Penido, Marcus L O ^b   Mendonça Previato, Lúcia ^e   Previato, José Oswaldo ^e   Ritter, Gerd ^f   Cunha, Fernando Q ^d   Gazzinelli, Ricardo T ^a,b,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; LIPOPEPTIDE; NY ESO 1 ANTIGEN; OVALBUMIN; PARACETAMOL; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR AGONIST; CTAG1B PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; FEMALE; INJECTION SITE PAIN; MELANOMA; MOUSE; NONHUMAN; PAIN ASSESSMENT; SPECIES COMPARISON; TRYPANOSOMA CRUZI; TUMOR IMMUNITY; ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); PROTOZOA; TRYPANOSOMA CRUZI;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; MELANOMA; MEMBRANE PROTEINS; MICE; T-LYMPHOCYTES; TRYPANOSOMA CRUZI;

EID: 84860430119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036245     Document Type: Article

References (59)

1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT, (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32.
2. Scanlan MJ, Simpson AJ, Old LJ, (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4: 1.
3. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, et al. (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161: 3598-3606.
4. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, et al. (2002) NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62: 213-218.
5. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270.
6. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, et al. (2006) In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 116: 1946-1954.
7. Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, et al. (2009) Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 27: 6854-6861.
8. Nishikawa H, Tsuji T, Jager E, Briones G, Ritter G, et al. (2008) Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 111: 1404-1412.
9. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, et al. (2009) NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15: 2130-2139.
10. Kawai T, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
11. Takeuchi O, Akira S, (2010) Pattern recognition receptors and inflammation. Cell 140: 805-820.
12. Iwasaki A, Medzhitov R, (2010) Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
13. Mosmann TR, Coffman RL, (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173.
14. Sallusto F, Lanzavecchia A, Araki K, Ahmed R, (2010) From vaccines to memory and back. Immunity 33: 451-463.
15. Adams S, (2009) Toll-like receptor agonists in cancer therapy. Immunotherapy 1: 949-964.
16. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R, (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188: 177-182.
17. Heath WR, Carbone FR, (2009) Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10: 1237-1244.
18. Coffman RL, Sher A, Seder RA, (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
19. Krieg AM, (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27: 161-167.
20. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, et al. (2001) Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol 167: 416-423.
21. Oliveira AC, Peixoto JR, de Arruda LB, Campos MA, Gazzinelli RT, et al. (2004) Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 173: 5688-5696.
22. Bartholomeu DC, Ropert C, Melo MB, Parroche P, Junqueira CF, et al. (2008) Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi. J Immunol 181: 1333-1344.
23. Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, et al. (1999) Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 274: 33419-33425.
24. Maraskovsky E, Sjolander S, Drane DP, Schnurr M, Le TT, et al. (2004) NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10: 2879-2890.
25. Aida Y, Pabst MJ, (1990) Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195.
26. Parker KC, Bednarek MA, Coligan JE, (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152: 163-175.
27. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S, (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
28. Previato JO, Gorin PA, Mazurek M, Xavier MT, Fournet B, et al. (1990) Primary structure of the oligosaccharide chain of lipopeptidophosphoglycan of epimastigote forms of Trypanosoma cruzi. J Biol Chem 265: 2518-2526.
29. Parada CA, Vivancos GG, Tambeli CH, Cunha FQ, Ferreira SH, (2003) Activation of presynaptic NMDA receptors coupled to NaV1.8-resistant sodium channel C-fibers causes retrograde mechanical nociceptor sensitization. Proc Natl Acad Sci U S A 100: 2923-2928.
30. Cunha TM, Verri WA Jr, Vivancos GG, Moreira IF, Reis S, et al. (2004) An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res 37: 401-407.
31. Zinkernagel RM, Hengartner H, (2006) Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol Rev 211: 310-319.
32. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
33. Kaufmann SH, (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33: 567-577.
34. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, et al. (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 104: 8947-8952.
35. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
36. Miller CH, Maher SG, Young HA, (2009) Clinical Use of Interferon-gamma. Ann N Y Acad Sci 1182: 69-79.
37. Donnelly JJ, Wahren B, Liu MA, (2005) DNA vaccines: progress and challenges. J Immunol 175: 633-639.
38. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, et al. (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156: 224-231.
39. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, et al. (1997) Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394.
40. Singh R, Wallecha A, (2011) Cancer immunotherapy using recombinant Listeria monocytogenes: Transition from bench to clinic. Hum Vaccin 7.
41. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
42. Seder RA, Gazzinelli R, Sher A, Paul WE, (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 90: 10188-10192.
43. Kis-Toth K, Szanto A, Thai TH, Tsokos GC, (2011) Cytosolic DNA-Activated Human Dendritic Cells Are Potent Activators of the Adaptive Immune Response. J Immunol 187: 1222-1234.
44. Rakoff-Nahoum S, Medzhitov R, (2009) Toll-like receptors and cancer. Nature Reviews Cancer 9: 57-63.
45. Yang Y, Huang CT, Huang X, Pardoll DM, (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5: 508-515.
46. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, et al. (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176: 7335-7345.
47. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-U136.
48. Gazzinelli RT, Ropert C, Campos MA, (2004) Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol Rev 201: 9-25.
49. Gazzinelli RT, Denkers EY, (2006) Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 6: 895-906.
50. Aliberti JC, Cardoso MA, Martins GA, Gazzinelli RT, Vieira LQ, et al. (1996) Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 64: 1961-1967.
51. Campos MA, Closel M, Valente EP, Cardoso JE, Akira S, et al. (2004) Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol 172: 1711-1718.
52. Camargo MM, Almeida IC, Pereira ME, Ferguson MA, Travassos LR, et al. (1997) Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages. J Immunol 158: 5890-5901.
53. Almeida IC, Camargo MM, Procopio DO, Silva LS, Mehlert A, et al. (2000) Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents. Embo J 19: 1476-1485.
54. Caetano BC, Carmo BB, Melo MB, Cerny A, dos Santos SL, et al. (2011) Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi. J Immunol 187: 1903-1911.
55. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, et al. (2006) Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 177: 3515-3519.
56. Su L, Tucker R, Frey SE, Gress JO, Chan IS, et al. (2000) Measuring injection-site pain associated with vaccine administration in adults: a randomised, double-blind, placebo-controlled clinical trial. J Epidemiol Biostat 5: 359-365.
57. Taddio A, Ilersich AL, Ipp M, Kikuta A, Shah V, (2009) Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials. Clin Ther 31 (Suppl 2): S48-76.
58. Shah V, Taddio A, Rieder MJ, (2009) Effectiveness and tolerability of pharmacologic and combined interventions for reducing injection pain during routine childhood immunizations: systematic review and meta-analyses. Clin Ther 31 (Suppl 2): S104-151.
59. Anderson BJ, (2008) Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth 18: 915-921.